List of Vaccines Companies in Texas - 12

As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,100 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit: BSWHealth.com.

Diakonos is a clinical-stage biotechnology company developing a groundbreaking Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers.

Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product is the TLPO vaccine, an autologous therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer. Therapeutic cancer vaccines are an attractive immunotherapy because of their potential safety, specificity, and long-lasting response due to stimulation of immune memory.

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

Impact Biomedical, Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Memgen is a clinical-stage biotech company developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from infectious diseases. The Company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already demonstrated the ability to elicit powerful, antigen-specific immune responses. The Company’s lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen is close to completing the monotherapy part of a clinical trial in advanced/metastatic NSCLC. Memgen's vaccine adjuvant, MemVax, is designed to be used in combination with other vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials, and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary vaccines.

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Texas Biomedical Research Institute is a biomedical research institute that focuses on advancing global health through innovative research.

Animal Vaccines

VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing "Advance Personalized Medicine" to medical professionals and patients globally". Our strategy increases the goal of success and is implemented with key partners in the biotech and pharmaceutical industries. Our current focuse is on Alzheimer's Disease (AD) utilizing a breakthrough Therapeutic Vaccine which targets ABeta and TAU and an AD Biomarker for early stage detection.